{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:53:28Z","timestamp":1787313208816,"version":"build-2736575974"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["216329\/Z\/19\/Z"],"award-info":[{"award-number":["216329\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0241357","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T13:44:24Z","timestamp":1603806264000},"page":"e0241357","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4711-9215","authenticated-orcid":true,"given":"Jake P.","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5165-9919","authenticated-orcid":true,"given":"Hesham K.","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardeep","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-4226","authenticated-orcid":true,"given":"Ranjit","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"pone.0241357.ref001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"key":"pone.0241357.ref002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"N Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0241357.ref003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"P Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"pone.0241357.ref004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.","volume":"43","author":"G Musso","year":"2011","journal-title":"Ann Med"},{"key":"pone.0241357.ref005","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3748\/wjg.v13.i10.1579","article-title":"Nonalcolholic fatty liver disease is a novel predictor cardiovascular disease","volume":"13","author":"M Hamaguchi","year":"2007","journal-title":"World J Gastroenterol"},{"key":"pone.0241357.ref006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2337\/dc17-1590","article-title":"Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission","volume":"41","author":"SH Wild","year":"2018","journal-title":"Diabetes Care"},{"key":"pone.0241357.ref007","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"H Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"pone.0241357.ref008","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"PS Dulai","year":"2017","journal-title":"Hepatology"},{"key":"pone.0241357.ref009","doi-asserted-by":"crossref","first-page":"e0173499","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-Alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"MH Le","year":"2017","journal-title":"PLoS One"},{"key":"pone.0241357.ref010","article-title":"Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study","author":"F Baratta","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0241357.ref011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S2468-1253(17)30142-5","article-title":"Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease","volume":"3","author":"IA Rowe","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0241357.ref012","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2468-1253(17)30365-5","article-title":"The painful reality of end-stage liver disease in NASH","volume":"3","author":"V. Ratziu","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0241357.ref013","doi-asserted-by":"crossref","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"M Alexander","year":"2019","journal-title":"BMJ"},{"key":"pone.0241357.ref014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases","volume":"27","author":"VT Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"pone.0241357.ref015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13059-018-1439-8","article-title":"Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption","volume":"19","author":"FWB Sanders","year":"2018","journal-title":"Genome Biol"},{"key":"pone.0241357.ref016","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"QM Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0241357.ref017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/TP.0000000000002484","article-title":"Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation","volume":"103","author":"ZM Younossi","year":"2019","journal-title":"Transplantation"},{"key":"pone.0241357.ref018","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1016\/S0016-5085(17)32415-0","article-title":"Diabetes, Heart Failure, and Chronic Kidney Disease are Risk Factors for Nafld-Related Cirrhosis: A Nationwide Analysis.","volume":"152","author":"SM Kilaru","year":"2017","journal-title":"Gastroenterology"},{"key":"pone.0241357.ref019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2017.03.038","article-title":"Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study","volume":"262","author":"F Angelico","year":"2017","journal-title":"Atherosclerosis"},{"key":"pone.0241357.ref020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/lt.25367","article-title":"Association of Pre-Transplant Renal Function with Liver Graft and Patient Survival after Liver Transplantation in Patients with Nonalcoholic Steatohepatitis","volume":"25","author":"MZ Molnar","year":"2019","journal-title":"Liver Transplant"},{"key":"pone.0241357.ref021","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"D Kim","year":"2013","journal-title":"Hepatology"},{"key":"pone.0241357.ref022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"M Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"pone.0241357.ref023","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"M Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"pone.0241357.ref024","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/00207454.2014.930463","article-title":"Co-morbidities and mortality associated with intracranial bleeds and ischaemic stroke","volume":"125","author":"J Sangha","year":"2015","journal-title":"Int J Neurosci"},{"key":"pone.0241357.ref025","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/jir.12196","article-title":"Risk factors for mortality in Down syndrome","volume":"59","author":"H Uppal","year":"2015","journal-title":"J Intellect Disabil Res"},{"key":"pone.0241357.ref026","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ijcard.2014.07.097","article-title":"The role of angioplasty in patients with acute coronary syndrome and previous coronary artery bypass grafting","volume":"176","author":"R Potluri","year":"2014","journal-title":"Int J Cardiol"},{"key":"pone.0241357.ref027","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijcard.2014.03.116","article-title":"Trends of cardiovascular disease amongst psychiatric patients between 2001 and 2012 in Greater Manchester, UK","volume":"173","author":"P Carter","year":"2014","journal-title":"Int J Cardiol"},{"key":"pone.0241357.ref028","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijcard.2017.06.033","article-title":"The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: Insights from the, United Kingdom ACALM registry","volume":"252","author":"OJ Ziff","year":"2018","journal-title":"Int J Cardiol"},{"key":"pone.0241357.ref029","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijcard.2016.03.198","article-title":"The prevalence of atrial fibrillation amongst heart failure patients increases with age","volume":"214","author":"F Ziaei","year":"2016","journal-title":"Int J Cardiol"},{"key":"pone.0241357.ref030","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.gastro.2020.04.039","article-title":"Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum","volume":"159","author":"M Noureddin","year":"2020","journal-title":"Gastroenterology"},{"key":"pone.0241357.ref031","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"key":"pone.0241357.ref032","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"C Estes","year":"2018","journal-title":"Hepatology"},{"key":"pone.0241357.ref033","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.13973","article-title":"Cardiovascular risk factors in non-alcoholic fatty liver disease","volume":"39","author":"H Hagstr\u00f6m","year":"2019","journal-title":"Liver Int"},{"key":"pone.0241357.ref034","doi-asserted-by":"crossref","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis","volume":"6","author":"S Wu","year":"2016","journal-title":"Sci Rep"},{"key":"pone.0241357.ref035","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.3748\/wjg.v21.i22.6820","article-title":"Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update","volume":"21","author":"VG Athyros","year":"2015","journal-title":"World J Gastroenterol"},{"key":"pone.0241357.ref036","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.dld.2018.09.004","article-title":"Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"50","author":"K Wijarnpreecha","year":"2018","journal-title":"Dig Liver Dis"},{"key":"pone.0241357.ref037","doi-asserted-by":"crossref","first-page":"e57183","DOI":"10.1371\/journal.pone.0057183","article-title":"Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes.","volume":"8","author":"G Targher","year":"2013","journal-title":"PLoS One"},{"key":"pone.0241357.ref038","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.01.009","article-title":"Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension","volume":"60","author":"KC Sung","year":"2014","journal-title":"J Hepatol"},{"key":"pone.0241357.ref039","doi-asserted-by":"crossref","first-page":"e0194153","DOI":"10.1371\/journal.pone.0194153","article-title":"Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The reasons for geographic and racial differences in stroke cohort","volume":"13","author":"KS Alexander","year":"2018","journal-title":"PLoS One"},{"key":"pone.0241357.ref040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13992","article-title":"Chronic Kidney Disease is Independently Associated with Increased Mortality in Patients with Non-alcoholic Fatty Liver Disease","volume":"39","author":"J Paik","year":"2019","journal-title":"Liver Int"},{"key":"pone.0241357.ref041","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2018.04.129","article-title":"Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure","volume":"265","author":"F Valbusa","year":"2018","journal-title":"Int J Cardiol"},{"key":"pone.0241357.ref042","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.14976","article-title":"Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany","volume":"48","author":"C Labenz","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0241357.ref043","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1148\/radiol.10100013","article-title":"Decompensated Chronic Heart Failure: Increased Liver Stiffness Measured by Means of Transient Elastography","volume":"257","author":"A Colli","year":"2010","journal-title":"Radiology"},{"key":"pone.0241357.ref044","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/apt.15660","article-title":"Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease","volume":"51","author":"JB Henson","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"pone.0241357.ref045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s00246-012-0447-9","article-title":"The relationship between pediatric nonalcoholic fatty liver disease and cardiovascular risk factors and increased risk of atherosclerosis in obese children","volume":"34","author":"S G\u00f6k\u00e7e","year":"2013","journal-title":"Pediatr Cardiol"},{"key":"pone.0241357.ref046","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2020.03.006","article-title":"Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping","volume":"73","author":"Z Liu","year":"2020","journal-title":"J Hepatol"},{"key":"pone.0241357.ref047","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.20251","article-title":"Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss","volume":"39","author":"JB Dixon","year":"2004","journal-title":"Hepatology"},{"key":"pone.0241357.ref048","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum Mediterranean and Low Fat Diets both Significantly Reduce Hepatic Steatosis: a Randomized Controlled Trial","volume":"68","author":"C Properzi","year":"2018","journal-title":"Hepatology"},{"key":"pone.0241357.ref049","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.amjmed.2014.10.014","article-title":"The Mediterranean diet, its components, and cardiovascular disease","volume":"128","author":"RJ Widmer","year":"2015","journal-title":"Am J Med"},{"key":"pone.0241357.ref050","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","article-title":"Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical","volume":"113","author":"P Poirier","year":"2006","journal-title":"Circulation"},{"key":"pone.0241357.ref051","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement","volume":"71","author":"VG Athyros","year":"2017","journal-title":"Metabolism"},{"key":"pone.0241357.ref052","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review","volume":"73","author":"EP Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"pone.0241357.ref053","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1570161117666190405164313","article-title":"Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block","volume":"18","author":"VG Athyros","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"pone.0241357.ref054","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.1016\/j.metabol.2019.07.009","article-title":"Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: Ex quo et quo vadimus?","volume":"98","author":"N Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"pone.0241357.ref055","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/bmj.322.7281.276","article-title":"How are abnormal results for liver function tests dealt with in primary care? Audit of yeild and impact","volume":"322","author":"P Sherwood","year":"2001","journal-title":"BMJ"},{"key":"pone.0241357.ref056","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA Clinical Practice Update: Coagulation in Cirrhosis","volume":"157","author":"JG O\u2019Leary","year":"2019","journal-title":"Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T14:29:47Z","timestamp":1696948187000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241357"}},"subtitle":[],"editor":[{"given":"Michael W.","family":"Greene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0241357","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2019.12.24.19015750","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]}}}